Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 760500
                    [Title] => New indication timely gift for type 2 diabetes patients
                    [Summary] => 
With the many sumptuous feasts and gastronomic temptations it brings, the Christmas season is often a dilemma for patients with diabetes trying to keep their blood sugar level in check.
                    [DatePublished] => 2011-12-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 719783
                    [Title] => Arthritis drug launched
                    [Summary] => 
Pain relief for patients with chronic arthritis has always been problematic because non-steroidal anti-inflammatory drugs (NSAIDs), one of the most widely prescribed agents for these conditions, cause gastrointestinal side effects such as stomach ulcers.
                    [DatePublished] => 2011-08-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 638698
                    [Title] => Gird up against GERD
                    [Summary] => 
You can be a candidate for GERD this holiday season. GERD is the acronym for gastro-esophageal reflux disease, a condition where gastric juices containing acid travel back from the stomach to the esophagus.
                    [DatePublished] => 2010-12-14 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1422176
                    [AuthorName] => Joy Angelica  Subido
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 630709
                    [Title] => Better GERD diagnosis, treatment pushed
                    [Summary] => 
Research-based pharmaceutical company AstraZeneca is working with specialists to “localize” a patient questionnaire that can help primary care physicians better diagnose gastroesophageal reflux disease (GERD), a common digestive disorder that is often undiagnosed, untreated and improperly managed.
                    [DatePublished] => 2010-11-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 626492
                    [Title] => AstraZeneca's gefitinib gets FDA approval
                    [Summary] => 
Research-based pharmaceutical company AstraZeneca’s targeted cancer therapy gefitinib has received approval from the Philippine Food and Drug Administration (FDA) as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
                    [DatePublished] => 2010-11-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 603626
                    [Title] => Partnership forged to curb diabetes cases
                    [Summary] => 
Alarmed at the growing prevalence of diabetes in the country, societies dealing with the epidemic of type 2 diabetes, including the American Association of Clinical Endocrinologists (AACE) Philippine Chapter and Diabetes Philippines (DP), have partnered with research-based biopharmaceutical company AstraZeneca to increase public awareness on diabetes prevention and management.
                    [DatePublished] => 2010-08-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 584585
                    [Title] => AstraZeneca's anti-cholesterol drug shows benefits in cardiovascular disease management
                    [Summary] => 
Two recent studies have shown that the AstraZeneca anti-cholesterol drug rosuvastatin demonstrated ability to reduce the risk of cardiovascular disease and is better than simvastatin and atorvastatin in the overall management of hypercholesterolemia.
                    [DatePublished] => 2010-06-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 530595
                    [Title] => AstraZeneca 'personalized healthcare' customizes treatments for patients
                    [Summary] => 
Guided by a better understanding of diseases and the differences among patients, one of the world’s leading pharmaceutical companies, AstraZeneca, is adopting a “personalized” approach to healthcare, particularly in developing targeted cancer treatments.
                    [DatePublished] => 2009-12-10 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [8] => Array
                (
                    [ArticleID] => 14809
                    [Title] => Novartis gears up for Biocamp 2007
                    [Summary] => 
            
                    [DatePublished] => 2007-08-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

AMAL KELSHIKAR

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 760500
                    [Title] => New indication timely gift for type 2 diabetes patients
                    [Summary] => 
With the many sumptuous feasts and gastronomic temptations it brings, the Christmas season is often a dilemma for patients with diabetes trying to keep their blood sugar level in check.
                    [DatePublished] => 2011-12-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 719783
                    [Title] => Arthritis drug launched
                    [Summary] => 
Pain relief for patients with chronic arthritis has always been problematic because non-steroidal anti-inflammatory drugs (NSAIDs), one of the most widely prescribed agents for these conditions, cause gastrointestinal side effects such as stomach ulcers.
                    [DatePublished] => 2011-08-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 638698
                    [Title] => Gird up against GERD
                    [Summary] => 
You can be a candidate for GERD this holiday season. GERD is the acronym for gastro-esophageal reflux disease, a condition where gastric juices containing acid travel back from the stomach to the esophagus.
                    [DatePublished] => 2010-12-14 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1422176
                    [AuthorName] => Joy Angelica  Subido
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 630709
                    [Title] => Better GERD diagnosis, treatment pushed
                    [Summary] => 
Research-based pharmaceutical company AstraZeneca is working with specialists to “localize” a patient questionnaire that can help primary care physicians better diagnose gastroesophageal reflux disease (GERD), a common digestive disorder that is often undiagnosed, untreated and improperly managed.
                    [DatePublished] => 2010-11-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 626492
                    [Title] => AstraZeneca's gefitinib gets FDA approval
                    [Summary] => 
Research-based pharmaceutical company AstraZeneca’s targeted cancer therapy gefitinib has received approval from the Philippine Food and Drug Administration (FDA) as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
                    [DatePublished] => 2010-11-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 603626
                    [Title] => Partnership forged to curb diabetes cases
                    [Summary] => 
Alarmed at the growing prevalence of diabetes in the country, societies dealing with the epidemic of type 2 diabetes, including the American Association of Clinical Endocrinologists (AACE) Philippine Chapter and Diabetes Philippines (DP), have partnered with research-based biopharmaceutical company AstraZeneca to increase public awareness on diabetes prevention and management.
                    [DatePublished] => 2010-08-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 584585
                    [Title] => AstraZeneca's anti-cholesterol drug shows benefits in cardiovascular disease management
                    [Summary] => 
Two recent studies have shown that the AstraZeneca anti-cholesterol drug rosuvastatin demonstrated ability to reduce the risk of cardiovascular disease and is better than simvastatin and atorvastatin in the overall management of hypercholesterolemia.
                    [DatePublished] => 2010-06-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 530595
                    [Title] => AstraZeneca 'personalized healthcare' customizes treatments for patients
                    [Summary] => 
Guided by a better understanding of diseases and the differences among patients, one of the world’s leading pharmaceutical companies, AstraZeneca, is adopting a “personalized” approach to healthcare, particularly in developing targeted cancer treatments.
                    [DatePublished] => 2009-12-10 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [8] => Array
                (
                    [ArticleID] => 14809
                    [Title] => Novartis gears up for Biocamp 2007
                    [Summary] => 
            
                    [DatePublished] => 2007-08-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest